<table>
<thead>
<tr>
<th>Condition</th>
<th>Sub-Condition</th>
<th>Cu-IUD</th>
<th>LNG-IUD</th>
<th>Implant</th>
<th>DMPA</th>
<th>POP</th>
<th>CHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Menarche</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>&lt;20 yrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥20 yrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥40 yrs.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anatomical abnormalities</td>
<td>a) Distorted uterine cavity</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>b) Other abnormalities</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>C</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td>Cervical intraepithelial neoplasia</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td>Deep venous thrombosis (DVT)/Pulmonary embolism (PE)</td>
<td>a) History of DVT/PE, not receiving anticoagulant therapy</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Higher risk for recurrent DVT/PE</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Lower risk for recurrent DVT/PE</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Acute DVT/PE</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>DVT/PE and established anticoagulant therapy for at least 3 months</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Higher risk for recurrent DVT/PE</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Lower risk for recurrent DVT/PE</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Family history (first-degree relatives)</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Major surgery</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>a) With prolonged immobilization</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>b) Without prolonged immobilization</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>Minor surgery without immobilization</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
</tr>
</tbody>
</table>

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)

** Smoke/abuse**

- 1

**Cystic fibrosis**

- I

**Deep Venous Thrombosis**

- a) History of DVT/PE, not receiving anticoagulant therapy
- b) Higher risk for recurrent DVT/PE
- c) Lower risk for recurrent DVT/PE

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)

**Cystic fibrosis**

- I

**Deep Venous Thrombosis**

- a) History of DVT/PE, not receiving anticoagulant therapy
- b) Higher risk for recurrent DVT/PE
- c) Lower risk for recurrent DVT/PE

- If on treatment, see Drug Interactions

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)

**Cystic fibrosis**

- I

**Deep Venous Thrombosis**

- a) History of DVT/PE, not receiving anticoagulant therapy
- b) Higher risk for recurrent DVT/PE
- c) Lower risk for recurrent DVT/PE

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)

**Cystic fibrosis**

- I

**Deep Venous Thrombosis**

- a) History of DVT/PE, not receiving anticoagulant therapy
- b) Higher risk for recurrent DVT/PE
- c) Lower risk for recurrent DVT/PE

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)

**Cystic fibrosis**

- I

**Deep Venous Thrombosis**

- a) History of DVT/PE, not receiving anticoagulant therapy
- b) Higher risk for recurrent DVT/PE
- c) Lower risk for recurrent DVT/PE

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)

**Cystic fibrosis**

- I

**Deep Venous Thrombosis**

- a) History of DVT/PE, not receiving anticoagulant therapy
- b) Higher risk for recurrent DVT/PE
- c) Lower risk for recurrent DVT/PE

**Diabetes**

- a) History of gestational disease
- b) Nonvascular disease
  - i) Non-insulin dependent
  - ii) Insulin dependent
- c) Nephropathy/retinopathy/neuropathy
- d) Other vascular disease or diabetes of >20 years duration

**Dysmenorrhea**

- Severe

**Endometrial cancer**

- 4

**Endometrial hyperplasia**

- 2

**Endometriosis**

- 2

**Epilepsy**

- (see also Drug Interactions)
<table>
<thead>
<tr>
<th>Condition</th>
<th>Sub-Condition</th>
<th>Cu-IUD</th>
<th>LNG-IUD</th>
<th>Implant</th>
<th>DMPA</th>
<th>POP</th>
<th>CHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>a) Adequately controlled hypertension</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>b) Elevated blood pressure level</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>i) Systolic 140-159 or diastolic 90-99</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>3*</td>
</tr>
<tr>
<td></td>
<td>ii) Systolic &gt;160 or diastolic &gt;100</td>
<td>1*</td>
<td>2*</td>
<td>2*</td>
<td>3*</td>
<td>2*</td>
<td>4*</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>C</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3/4*</td>
</tr>
<tr>
<td></td>
<td>(ulcerative colitis, Crohn’s disease)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3/4*</td>
</tr>
<tr>
<td>Thrombotic heart disease</td>
<td>C</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3/4*</td>
</tr>
<tr>
<td></td>
<td>Current and history of</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Known thrombogenic mutations</td>
<td>C</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Liver tumors</td>
<td>a) Benign</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>b) Focal nodular hyperplasia</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>ii) Hepatocellular adenoma</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>b) Malignant (hepatoma)</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Malarias</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Multiple risk factors for atherosclerotic cardiovascular disease</td>
<td>(e.g., older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels)</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3*</td>
<td>2*</td>
<td>3/4*</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>a) With prolonged immobilization</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Without prolonged immobilization</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Obesity</td>
<td>a) Body mass index (BMI) ≥ 30 kg/m²</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Menarche to &lt;18 years and BMI ≥ 30 kg/m²</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td>a) Nulliparous</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>b) Parous</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Past ectopic pregnancy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Pelvic inflammatory disease</td>
<td>a) Past</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>i) With subsequent pregnancy</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>ii) Without subsequent pregnancy</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Penicillin-resistant syphilis</td>
<td>1*</td>
<td>2*</td>
<td>4*</td>
<td>4*</td>
<td>1*</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a) Normal or mildly impaired cardiac function</td>
<td>1*</td>
<td>2*</td>
<td>4*</td>
<td>4*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>b) Severe arterial disease</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Postpartum (nonbreastfeeding women)</td>
<td>b) 21 days to 42 days</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>i) With other risk factors for VTE</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ii) Without other risk factors for VTE</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Postpartum (in breastfeeding or non-breastfeeding women, including cesarean delivery)</td>
<td>a) Within 72 hours after delivery of the placenta</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>b) Within 28 days</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>1*</td>
</tr>
<tr>
<td></td>
<td>c) After 28 days</td>
<td>1*</td>
<td>1*</td>
<td>1*</td>
<td>2*</td>
<td>1*</td>
<td>1*</td>
</tr>
</tbody>
</table>

**Notes:**
- Cu-IUD: Copper Intrauterine Device
- LNG-IUD: Levonorgestrel Intrauterine Device
- Implant: Progesterone Implant
- DMPA: Depo-Provera
- POP: Pills
- CHC: Contraceptive Hormonal Gel

**Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use**

This summary sheet only contains a subset of the recommendations from the U.S. MEC. For complete guidance, see: http://www.cdc.gov/reproductivehealth/MEC/MEC_Framework.asp

**Condition**

- **Pregnancy:**
  - On immunosuppressive therapy
  - Not on immunosuppressive therapy

- **Rheumatoid arthritis:**
  - On immunosuppressive therapy
  - Not on immunosuppressive therapy

- **Schistosomiasis:**
  - Uncomplicated
  - Fibrosis of the liver

- **Sexually transmitted diseases (STDs):**
  - Current or acute pelvic inflammatory disease
  - Vaginitis (including chlamydial or gonococcal infection)

- **Antiretroviral therapy:**
  - 1 or 2 for all methods.
  - All other ARV’s are drug interactions.

- **Viral hepatitis:**
  - None of the above

- **Drug Interactions:**
  - Fosamprenavir (FPV)

**Antiretroviral therapy**

- All ARV’s are drug interactions.

**Antimicrobial therapy**

- Broad spectrum antibiotics

**SRS:**

- St. John’s wort

**Updated in 2017:** This summary sheet only contains a subset of the recommendations from the U.S. MEC. For complete guidance, see: http://www.cdc.gov/reproductivehealth/MEC/MEC_Framework.asp. Most contraceptive methods do not protect against sexually transmitted diseases (STDs). Consistent and correct use of the male latex condom reduces the risk of STDs and HIV.